Veterinary Medicines

Fencovis, Suspension for injection

Authorised
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
  • Bovine coronavirus, strain C-197, Inactivated
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
Download as PDF

Product identification

Medicine name:
Fencovis RCE vet injeksjonsvæske, suspensjon
Fencovis, Suspension for injection
Active substance:
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
  • Bovine coronavirus, strain C-197, Inactivated
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
Target species:
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Bovine coronavirus, strain C-197, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Available in:
  • Norway
Package description:
  • Glass Vial 2 x 1.0 Dose
  • Glass Vial 10 x 1.0 Dose
  • Glass Vial 20 x 1.0 Dose
  • Glass Vial 1 x 5.0 Dose
  • Plastic Vial 1 x 5.0 Dose
  • Glass Vial 5 x 5.0 Dose
  • Plastic Vial 5 x 5.0 Dose
  • Glass Vial 10 x 5.0 Dose
  • Plastic Vial 10 x 5.0 Dose
  • Glass Vial 1 x 25.0 Dose
  • Plastic Vial 1 x 25.0 Dose
  • Glass Vial 12 x 25.0 Dose
  • Plastic Vial 12 x 25.0 Dose
  • Glass Vial 24 x 25.0 Dose
  • Plastic Vial 24 x 25.0 Dose
  • Glass Vial 1 x 50.0 Dose
  • Plastic Vial 1 x 50.0 Dose

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 21-14107
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0177/001
Concerned member states:
  • Austria
  • Belgium
  • Finland
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Package Leaflet

English (PDF)
Published on: 25/08/2022
Download
Norwegian (PDF)
Published on: 17/03/2025
Download

Labelling

English (PDF)
Published on: 25/08/2022
Download

Summary of Product Characteristics

English (PDF)
Published on: 25/08/2022
Download
Norwegian (PDF)
Published on: 17/03/2025
Download